Researchers have previously attempted to develop synthetic lung surfactants, but some have been removed from the market and others have not been able to lower surface tension as well as animal-derived formulations.
Experts have proposed a new definition for acute respiratory distress syndrome, reflecting recent research and advancements in diagnosis and treatment.
7% of the nation's more than 3,000 lung transplants between Aug. 1, 2020, and Sept. 30, 2021 were performed to treat severe, irreversible lung damage caused by COVID-19.
Patients with severe COVID-19 who develop ARDS have malfunctions in their immune systems that distinguish them from other COVID-19 patients.
Read More
The US FDA has issued an Emergency Use Authorization (EUA) for primary critical care use of CorVent Medical’s Respond-19 Ventilator.
Read More
High PEEP titration and prone positioning were as effective in treating early COVID-19 ARDS patients undergoing mechanical ventilation as classic ARDS.
Read More
According to the NAVIATOR trial, Getinge’s NAVA significantly increased the number of ventilator-free days and shortened the time of mechanical ventilation for adult patients with acute respiratory failure.
Read More
New research has found that having fewer types of fungi in the lungs is linked to increased severity of disease in acute respiratory distress syndrome patients.
Read More
The novel coronavirus is causing significant dilation of lung capillaries and this vasodilation is contributing to the very low oxygen levels seen in COVID-19 respiratory failure.
Read More
Research has shown that, among ICU survivors of COVID-19-related ARDS, the experience of “air hunger” (or severe dyspnea) is often associated with post-traumatic stress disorder.
Read More
Glucocorticoids are widely used in treating acute respiratory distress syndrome (ARDS), but a new study shows that this treatment could lead to higher death rates.
Read More
Researchers have been unable to produce two theorized subphenotypes of COVID-19 related ARDS, the more typical ‘H type’ and a variant ‘L type.’
Read More
A novel stem cell therapy using generation mesenchymal stem cells (MSCs) is in development for acute respiratory distress syndrome in COVID-19 patients.
Read More
Physicians in Italy report that a cohort of COVID-19 patients suffering from acute respiratory distress syndrome had well preserved lung gas volume but severe hypoxia, which they called “atypical” for ARDS.
Read More
Approximately 190,000 patients experience acute respiratory distress syndrome (ARDS) annually, and...
Read More